Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5848259 | 1.00 | CYP2D6 (0.51) | CYP2D6OPRK1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL5848257 | 1.00 | CYP2D6 (0.51) | CYP2D6OPRK1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL5847594 | 0.87 | CYP2D6 (0.53) | CYP2D6OPRK1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL5847599 | 0.87 | CYP2D6 (0.53) | CYP2D6OPRK1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL5847604 | 0.87 | CYP2D6 (0.53) | CYP2D6OPRK1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL5846927 | 0.78 | OPRK1 (0.47) | CYP2D6OPRK1HPGDPOLBAPEX1 | |
| SCHEMBL5846932 | 0.78 | OPRK1 (0.47) | CYP2D6OPRK1HPGDPOLBAPEX1 | |
| SCHEMBL5846930 | 0.78 | OPRK1 (0.47) | CYP2D6OPRK1HPGDPOLBAPEX1 | |
| SCHEMBL7289762 | 0.76 | CYP2D6 (0.40) | CYP2D6OPRK1SMN1; SMN2GAAHPGD | |
| SCHEMBL24193318 | 0.75 | TDP1 (0.46) | SMN1; SMN2HPGDPOLBAPEX1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7034051-B2 | Fused bicyclic carboxamide derivatives and methods of their use | ADOLOR CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| WO-2005023799-A1 | FUSED BICYCLIC CARBOXAMIDE DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20050054630-A1 | Fused bicyclic carboxamide derivatives and methods of their use | CUBIST PHARMACEUTICALS, INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054630-A1 | Fused bicyclic carboxamide derivatives and methods of their use | PAICS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CPS1 | CYP2D6 44/4885OPRK1 268/4885RAB9A 2526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.